• Optiscan unveils the InVue next-gen microscopic medical imaging device for precision surgery
  • InVue broadens Optiscan’s product portfolio into the surgical application market, a significant step forward in achieving its strategic objectives
  • The versatile imaging device is suitable for various clinical settings, particularly in cancer diagnosis and treatment adjustments

 

Special Report: Optiscan has soared after unveiling its ground-breaking new microscopic medical imaging device InVue, which is designed to enable precision surgery by putting real-time digital pathology access directly into the hands of surgeons.

The latest Optiscan (ASX:OIL) device leverages its patented technology and is designed to be used by surgeons to gain immediate pathology insights in the operating theatre, to enable on-the-spot decision making, treatment adjustments and precision surgery.

OIL says the quicker delivery of diagnosis insights marks a significant advancement in the field of pathology, traditionally performed in dedicated laboratories using analogue methods, separate from the operating room.

The company says the current pathology process is time-consuming, involves multiple steps, and delivers results to surgeons after considerable delays.

Designed and manufactured in Melbourne by OIL in partnership with Sydney and Melbourne-based industrial design firm Design + Industry, InVue is designed for ease of use in various clinical settings, such as cancer diagnosis and treatment.

The device provides surgeons with real-time microscopic imaging and pathology details, helping them to enhance the accuracy of their diagnoses and reduce the need for multiple diagnostic procedures and repeat surgeries.

 

The InVue imaging device. Pic: Optiscan

 

Lowering healthcare costs

Importantly, the InVue device is expected to achieve more than just enabling more precise treatment.

By enhancing the accuracy and speed of treatment, OIL says InVue should also help reduce healthcare costs and improve patient outcomes.

The device has a spatial resolution of 0.55μ, making it more than 1000 times more powerful than traditional CT and MRI scanners, which have a typical resolution of 0.5-1mm.

InVue is DICOM-compliant and PACS-enabled, designed to integrate with OIL’s cloud-based telepathology platform, forecast to be unveiled in 2025.

The telepathology platform will enable surgeons and pathologists to collaborate on surgical cases in real-time from anywhere in the world.

 

Global leader in confocal endomicroscopic imaging tech

OIL has become a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications.

The biotech’s technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level.

OIL recently announced it had entered a collaboration through a know-how agreement with the world-renowned Mayo Clinic with to develop an endomicroscopic imaging system for use in robotic surgery.

The collaboration combines OIL’s engineering expertise in digital endomicroscopic hardware and software development with Mayo’s know-how in robotic surgery and patient care.

 

‘Significant milestone’ 

CEO and managing director Dr Camile Farah, who is also a pathologist, says getting its next-gen InVue microscopic medical imaging device to the reveal stage is a real credit to the hard work of the entire OIL team.

“The reveal is much more than just a significant milestone in the company’s growth strategy,” he says.

“It paves the way for a significant evolution of digital pathology and precision surgery.”

Farah says InVue will bring digital pathology insights into the operating theatre and directly into the hands of surgeons.

“The end result will be enhanced speed and accuracy of treatment, which should in turn deliver improved patient outcomes,” he says.

“We are particularly excited by what the InVue, which tailors our patented technology to the surgical market, will mean for the future treatment and diagnosis of cancer patients.

“It will facilitate a dramatic step forward in the way cancer can be diagnosed and treated with unprecedented accuracy and precision.

The company’s first intended use of InVue is for breast cancer surgery and margin determination.

“This form of cancer is the most commonly diagnosed cancer amongst women in Australia, with over 20,000 Australians diagnosed each year.

“In the US, this number is as high as 300,000 per year, which is an important and large addressable market.”

 

This article was developed in collaboration with Optiscan, a Stockhead advertiser at the time of publishing. 

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.